Balancing Innovation and Risk Management in Biopharma Commercialization
MORRISTOWN, NJ, Published in Pharma Executive you will find RxC International’s latest whitepaper: Balancing Innovation and Risk Management in Biopharma Commercialization
OVERVIEW
A striking dichotomy exists between how biopharma companies and healthcare stakeholders perceive the value of biomedical innovation and novel drugs. Biopharma companies must work with key stakeholders to ensure that, upon approval, patients who would benefit from these novel treatments have timely access to them. Additionally, both innovation and risk management are important in commercializing these novel treatments. In this article, the RxC team profiles five key trends that are profoundly impacting the commercialization of novel treatments and their implications for biopharma companies.
Value-based healthcare is transforming the delivery of care
Consumerism in healthcare is a positive driving force
Personalized solutions are producing quality health outcomes
New technologies are enabling digital healthcare transformation
Supply chain networks are facilitating direct distribution models
Go to our website to download the whitepaper www.rxcinternational.com. We encourage you to review our perspectives on this topic and share your thoughts. You may reach us via info@RxCinternational.com.
ABOUT RXC INTERNATIONAL
RxC International is a premier life sciences management consulting firm with a passion for helping clients develop strategies to grow their business. Our consulting team has deep expertise in strategic planning, new product planning, and commercial excellence to maximize product potential for pipeline and marketed products. Our clients include leading pharmaceutical and biotechnology companies around the world. The firm has offices in New Jersey, Massachusetts, and California. Additional information about RxC International can be found at www.RxCInternational.com.
CONTACTS
RxC International
info@RxCInternational.com